



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Elisabettni et al.
Appl. No.: 10/044,234
Conf. No.: 8974
Filed: January 11, 2002
Title: BICARBONATE-BASED SOLUTIONS FOR DIALYSIS THERAPIES
Art Unit: 1616
Examiner: F. Choi
Docket No.: DI-5782

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

In accordance with the provisions of 37 C.F.R. 1.56, 37 C.F.R. 1.97, and 37 C.F.R. 1.98, Applicants request that a citation and examination of the references cited below, and on the attached PTO-1449 form, copies of which are enclosed, be made during the course of examination of the above-identified application for United States patent.

U.S. PATENT DOCUMENTS

<u>Document No.</u>	<u>Date</u>	<u>Inventor</u>
5,211,643	05/18/93	Reinhardt et al.
5,616,248	04/01/97	Schal
6,139,754	10/31/00	Hartranft et al.

FOREIGN PATENT DOCUMENTS

<u>Document No.</u>	<u>Date</u>	<u>Country</u>
EP 0602014	06/15/94	Europe
WO 01/17534	03/15/01	PCT

12/30/2004 MBERHE 00000011 10044234

01 FC:1806

180.00 0P


All of the cited references listed above are listed in the enclosed Australian Patent Office Written Opinion dated August 3, 2004 corresponding to the present application. A copy of the Written Opinion is included with this submission.

Applicants look forward to early and favorable consideration of this matter.

Respectfully submitted,

BELL, BOYD & LLOYD LLC

BY

A handwritten signature in black ink, appearing to read 'Robert M. Barrett', is written over a horizontal line.

Robert M. Barrett


Reg. No. 30,142

P.O. Box 1135

Chicago, Illinois 60690-1135

Phone: (312) 807-4204

Date: December 21, 2004



INFORMATION DISCLOSURE CITATION IN AN APPLICATION (Use several sheets if necessary) PTO Form 1449		Atty Docket No. DI-5782	Application No. 10/044,234
		Applicant Elisabettini et al.	
		Filing Date Jan. 11, 2002	Group 1616


U.S. PATENT DOCUMENTS							
Examiner's Initials		Document Number	Publication Date	Inventor	Class	Subclass	Filing Date If Appropriate
		5,211,643	05/18/93	Reinhardt et al.			
		5,616,248	04/01/97	Schal			
		6,139,754	10/31/00	Hartranft et al.			

FOREIGN PATENT DOCUMENTS								
Examiner's Initials		Document Number	Publication Date	Country	Class	Subclass	Translation	
							Yes	No
		EP 0602014	06/15/94	Europe				
		WO 01/17534	03/15/01	PCT				

Examiner's Initials		OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

Examiner:	Date Considered:
*Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Docket No.
DI-5782



Confirmation No.

8974


(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

- P10A/REV04

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.
DI-5782

In Re Application Of: Elisabettini et al.



Application No.	Filing Date	Examiner	Customer No.	Group Art Unit	Confirmation No.
10/044,234	January 11, 2002	F. Choi	29200	1616	8974

Title: **BICARBONATE-BASED SOLUTIONS FOR DIALYSIS THERAPIES**

Address to:
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

37 CFR 1.97(b)

1. ☐ The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.

37 CFR 1.97(c)

2. ☒ The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:

☐ the statement specified in 37 CFR 1.97(e);

OR

☒ the fee set forth in 37 CFR 1.17(p).